Sandoz concludes acquisition of Mycamine antifungal agent from Astellas

28 Aug 2023
www.pharmaceutical-technology.com
Drug ApprovalPhase 3AcquisitionClinical Result
Sandoz concludes acquisition of Mycamine antifungal agent from Astellas
Preview
Source: Pharmaceutical Technology
For the year ending 31 March this year, Astellas achieved sales of $105m for MycamineMycamine. Credit: BalkansCat / Shutterstock.com.
Novartis division Sandoz has concluded the acquisition of global brand rights for the antifungal agent Mycamine (micafungin sodium) from Astellas.
In January this year, Sandoz first signed an agreement to purchase the rights of MycamineMycamine from the Japanese company.
Recommended Reports
Sandoz concludes acquisition of Mycamine antifungal agent from Astellas
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Rivaroxaban in Antiphospholipid Syndrome GlobalData
Sandoz concludes acquisition of Mycamine antifungal agent from Astellas
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Rusfertide Acetate in Polycythemia Vera GlobalData
View all
Mycamine is intended for the treatment of invasive candidiasis and oesophagal candidiasis. It can also be used to prevent candida and aspergillus infections in patients undergoing hematopoietic stem cell transplantation.
The antifungal agent is said to be a therapy of choice in hospitals and intensive care units across the world.
For the year ending 31 March this year, the company achieved sales of JPY14.2bn ($105m) for MycamineMycamine.
Sandoz strengthens its worldwide hospital product range and collection of anti-infective solutions through the acquisition of this key global echinocandin.
Sandoz CEO Richard Saynor said: “This is another sign of our commitment at Sandoz to driving responsible access to critical antimicrobial medicines.
“We are both investing in our production network and selectively building out our leading portfolio in this field to ensure that we can continue to offer patients around the world the right medicine at the right time.”
This month, Sandoz unveiled plans to file for regulatory approval in the US and EU for its Eylea (aflibercept) biosimilar in the next few months.
The approval for the biosimilar would be based on the randomised Phase III trial showing the non-inferiority of the biosimilar compared to Bayer and Regeneron’s Eylea in wet age-related macular degeneration (wAMD).
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.